Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Blood and Lymphatic Cancer: Targets and Therapy · 2026-03 · Volume 16 · 1-8
DOI: 10.2147/blctt.s559759 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2026-03. Verfasst von Manuel R Espinoza-Gutarra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Acute Myeloid Leukemia (AML) is a common hematologic neoplasm in adults and usually carries a grim prognosis. Therapy has traditionally consisted of intensive chemotherapy; however, recent advances have led to the development of Tyrosine Kinase Inhibitors (TKI) as Targeted Therapies for subtypes carrying certain mutations. While the clinical impact of these therapies has been well described, there have been no studies looking at clinical disparities among different racial/ethnic groups receiving these therapies. We leveraged an EHR-derived database to evaluate real-world outcomes in patients receiving TKIs for AML. Our study found no significant differences between real-world Event Free Survival (rwEFS) and real world Overall Survival (rwOS) across patients of different racial/ethnic groups, this suggests that when patients have access to targeted therapy outcomes across different racial/ethnic groups become more equitable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL, USA.
- Flatiron Health, New York, NY, USA.
- Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
- Department of Biostatistics, Data Science and Epidemiology, Augusta University School of Public Health, Augusta, GA, USA.
- Department of Biostatistics, Data Science and Epidemiology, Georgia Cancer Center, Augusta, GA, USA.
ORCID-Profile: Manuel R Espinoza-Gutarra
Zitieren
APA
Espinoza-Gutarra, M. R., Jarrett, B. A., Wang, X., Afghahi, A., & Bae, S. (2026). Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. Blood and Lymphatic Cancer: Targets and Therapy, Volume 16, 1-8. https://doi.org/10.2147/blctt.s559759
Vancouver
Espinoza-Gutarra MR, Jarrett BA, Wang X, Afghahi A, Bae S. Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2. Blood and Lymphatic Cancer: Targets and Therapy. 2026;Volume 16:1-8. doi:10.2147/blctt.s559759
BibTeX
@article{EspinozaGutarra2026,
author = {Espinoza-Gutarra, Manuel R and Jarrett, Brooke A and Wang, Xiaoliang and Afghahi, Anosheh and Bae, Sejong},
title = {Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2026},
volume = {Volume 16},
pages = {1--8},
doi = {10.2147/blctt.s559759}
}
EUVIMED